Hello and welcome to this analysis Glenmark after consolidating near its monthly support attempted a fresh upmove from 350 to 400, Post that it has made a sideways corrective forming a Bullish Harmonic ABCD. The current reversal from 375 could be a higher low of the new uptrend in it and it could rally till 410-425-450 as long as it does not breach 374....
Eli Lilly and Company ( NYSE:LLY ) Sector: Health Technology (Pharmaceuticals: Major) Market Capitalization: $315.073B Current Price: $331.60 Breakout price: $334.70 Buy Zone (Top/Bottom Range): $314.00-$292.90 Price Target: $364.20-$367.50 (2nd) Estimated Duration to Target: 112-120d (2nd) Contract of Interest: $LLY 10/21/22 350c Trade price as of publish...
Merck & Company, Inc. ( NYSE:MRK ) Sector: Health Technology (Pharmaceuticals: Major) Market Capitalization: $213.987B Current Price: $84.62 Breakout price: $91.40 Buy Zone (Top/Bottom Range): $83.60-$79.90 Price Target: $103.20-$105.80 Estimated Duration to Target: 672-696d Contract of Interest: $MRK 1/19/24 85c Trade price as of publish date: $10.17/contract
New York-based pharmaceutical firm SIGA Technologies (NASDAQ:SIGA) is among the companies to benefit from the growing threat of monkeypox, recently pushing its shares to an almost decade-high after the company obtained approval in Europe to use its TPOXX antiviral drug for the treatment of monkeypox. Smallpox jabs vs monkeypox On May 19, the World Health...
were up 15% AH and trying to consolidate if we can hold the $0.49 area and stay out of oversold stoch on the daily beating $0.545 and breaking $0.668 level stock should revisit the $0.71-$0.78 area predicting rangebound price action
Buy Torrent Pharma above 2905 for the targets of 3017/3067/3100
ARDS Aridis Pharmaceuticals has 2 Phase 3 Clinical Trials for 2022, one Phase 2a study, a fully human monoclonal antibody (mAb) cocktail against COVID and a funding from the Gates Foundation to support development of inhaled formulation technology to deliver cost-effective monoclonal antibodies against influenza and COVID-19. And the Market Cap is only...
CIPLA LTD shows a breakout of 1 year consolidation . It shows a strong Breakout in the range of Support and Resistance the price shows a multiple touches in the top and bottom in the zone . wait for a retest and go for a buy
The stock has broken out and retested, therefore may undergo a reversal rally. Trade is supported by Supports Nearby. Risk Reward Ratio - 2:1 SL is placed below the support zone & the lower trendline. The target is placed near resistance.
The stock has broken out and retested, therefore may undergo a reversal rally. Trade is supported by brokerage calls and Supports Nearby. Risk Reward Ratio - 2:1 SL is placed below the support zone & the lower trendline. The target is placed near resistance.
The stock has broken out and retested, therefore may undergo a reversal rally. Trade is supported by brokerage calls and Supports Nearby. Risk Reward Ratio - 2:1 SL is placed below support zone & the lower trendline. The target is placed near resistance.
The stock has broken out and retested, therefore may undergo a reversal rally. Trade is supported by brokerage calls and Supports Nearby. Risk Reward Ratio - 2:1 SL is placed below support zone & the lower trendline. The target is placed near resistance.
The stock has reached lower trendline and may undergo a reversal rally. Trade is supported by brokerage calls and Supports Nearby. Risk Reward Ratio - 2:1 SL is placed below support zone & the lower trendline. The target is placed near resistance. Market is bearish, so take positions carefully.
NASDAQ:ABEO I have been watching ABEO for about a month now. ABEO has the potential to make a few bucks but is relatively high on risk. I hesitate parking too much money here for too long but do believe this will reap rewards in 6-12 months. Some reasoning goes as follows: 1) Legitimate company that is in the middle of working on multiple gene therapy products...
The stock has reached lower trendline and may undergo a reversal rally. Trade is supported by brokerage calls and Supports Nearby. Risk Reward Ratio - 3:1 SL is placed below support zone & the lower trendline. The target is placed near resistance.
Considering last week candle, NSE:AUROPHARMA has already given confirmation of further sign of selling . Price has created harmonic Shark pattern with PRZ level 0.886 and 1.13 with price 651.70 and 548.75 respectively. As we have witnessed of bounce from 0.886 level but not sustained above 200 MA. Two things are possible here : 1. It again takes confirmation...
DIVISLAB have taken support and forming pole and flag . Going to break channel and start up move. Targets are mentioned, must comment if have any suggestion. NSE:DIVISLAB
The stock has reached lower trendline and may undergo a reversal rally. Trade is supported by brokerage calls and Supports Nearby. Risk Reward Ratio - 3:1 SL is placed below support zone & the lower trendline. The target is placed near resistance.